- Syneos Health ( NASDAQ: SYNH ) is collaborating with Haystack Health to improve the identification and enrollment of patients for clinical trials using artificial intelligence (AI).
- Haystack is a Roivant Health portfolio company which develops AI and Natural Language Processing (NLP) solutions, according to Syneos.
- The company said that for sponsors and sites, the partnership will deliver research tools and workflow efficiencies which will result in improved timelines and increased patient recruitment.
- Initially, these new data solutions will only be available for Syneos sites in the U.S., with a focus on oncology and immunology.
- The companies noted that they have been collaborating directly with sites and sponsors over several months and have been able to identify eligible patients for specific trials in near-real time.
- "By more thoroughly validating study inclusion/exclusion criteria during pre-screening, the chances of pushing an ineligible patient to final screening are dramatically reduced," said Haystack CEO Steve Whitehurst.
For further details see:
Syneos, Haystack team up to use AI to identify patients for clinical trials